Moreover, we found that IGSF6 manifests a favorable expression trajectory in the MMR-proficient as compared to MMR-deficient in CRC (Supplementary Fig. 2), which suggested the potential role of IGSF6 as a potential biomarker of cancer therapy in MMR-proficient CRC. The gene discussed is IGSF6; the disease is cancer.